Summary of Phase 1 Zoldonrasib Data at AACR 2026 ( Abstract # CT021 ) ...

Engaging in moderate to vigorous physical activity, even below recommended levels, can significantly improve cancer survival ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

Many of us think we know the key causes and symptoms of lung cancer. However, there are still some misconceptions about the ...

An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...

Early results presented at a cancer research conference showed tumor shrinkage and slowed disease progression in patients who ...

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...

Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...

Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above ...

The Lung Cancer Research Foundation's 2026 Gala will spotlight women facing lung cancer with courage and resolve, women we have lost to the disease, and physicians and scientists whose leadership is ...

The incidence and mortality rate of esophageal cancer in China fell by around 4.5 percent annually, according to the figures ...